

SUPPLEMENTARY DATA

Table 1 of the supplementary data. Probabilities of clinical events used in the model

Clinical events	TAVI with SAPIEN 3	SAVR	Source
At 30 days			
Treated AF	4.1%	35.8%	PARTNER 3 trial ¹
New permanent pacemaker implantation	6.5%	4.0%	
Rehospitalization	3.4%	6.4%	
Disabling stroke	0.0%	0.4%	
Aortic reintervention	0.2%	0.7%	
Mortality	0.4%	1.1%	
Monthly health state transition probabilities and intercurrent events between 30 days and 1 year			
Alive and well → Treated AF	0.11%	0.15%	PARTNER 3 trial ¹
Alive and well → Disabling stroke	0.004%	0.004%	SAFE ²
Treated AF → Disabling stroke	0.009%	0.009%	Odutayo et al. 2016 ³
TIA	0.09%	0.04%	PARTNER 3 trial ¹
MI	0.02%	0.08%	
Severe or life-threatening bleeding	0.4%	0.1%	
Monthly health state transition probabilities > 1 year and beyond			
Alive and well → Treated AF	0.06%	0.11%	PARTNER 3 trial, 2-year outcomes ⁴
Alive and well → Disabling stroke	0.004%	0.004%	SAFE ²
Treated AF → Disabling stroke	0.01%	0.01%	Odutayo et al. 2016 ³
Events > 30 days (converted to monthly rates in calculations)			
Rehospitalization at 1 year	4.2%	4.8%	PARTNER 3 trial ¹
Rehospitalization at 2 years and beyond	1.2%	1.2%	PARTNER 3 trial, 2-year outcomes ⁴
Aortic reintervention (converted to monthly rates in calculations)			
From Year 1 to Year 23 onwards	From 0.5% to 8.9%	From 0.5% to 8.9%	PARTNER 3 trial, up to 2 years ^{1,4} and thereafter Bourguignon et al. 2015 ⁵

Table 2 of the supplementary data. Annual mortality risk for 'alive and well' and associated relative risk for other health states

Annual mortality risk - alive and well (by age)	Men	Women	Monthly probability for TAVI	Monthly probability for SAVR	Source
70 years	1.72%	0.75%	0.12%	0.12%	National life tables in Spain ⁶
71 years	2.00%	0.84%	0.14%	0.14%	
72 years	2.11%	0.90%	0.15%	0.15%	
73 years	2.34%	1.08%	0.16%	0.16%	
74 years	2.55%	1.17%	0.18%	0.18%	
75 years	2.81%	1.34%	0.20%	0.20%	
76 years	3.03%	1.53%	0.22%	0.22%	
77 years	3.17%	1.67%	0.23%	0.23%	
78 years	3.71%	1.90%	0.27%	0.27%	
79 years	4.13%	2.27%	0.30%	0.30%	
80 years	4.82%	2.62%	0.35%	0.35%	
81 years	5.35%	3.09%	0.40%	0.40%	
82 years	5.99%	3.60%	0.45%	0.45%	
83 years	6.77%	4.10%	0.51%	0.51%	
84 years	7.48%	4.87%	0.57%	0.57%	
85 years	8.56%	5.67%	0.66%	0.66%	
86 years	9.59%	6.57%	0.75%	0.75%	
87 years	10.60%	7.65%	0.85%	0.85%	
88 years	12.16%	8.78%	0.98%	0.98%	
89 years	13.29%	9.98%	1.08%	1.08%	
90 years	15.04%	11.80%	1.25%	1.25%	
91 years	16.37%	13.19%	1.38%	1.38%	
92 years	18.42%	14.98%	1.58%	1.58%	
93 years	19.86%	16.48%	1.72%	1.72%	
94 years	21.22%	17.95%	1.86%	1.86%	
95 years	21.91%	20.28%	1.99%	1.99%	
96 years	24.01%	21.90%	2.19%	2.19%	
97 years	26.62%	23.86%	2.45%	2.45%	
98 years	26.75%	24.86%	2.50%	2.50%	
99 years	26.55%	26.05%	2.52%	2.52%	
100 years	26.55%	26.05%	2.52%	2.52%	
Relative risk of death (HR) associated with treated AF, disabling stroke, and reintervention					
Treated AF	HR, 1.46	Odutayo et al. 2016 ³			

Vázquez Rodríguez JM, et al. Cost-effectiveness of SAPIEN 3 transcatheter aortic valve implantation in low surgical mortality risk patients in Spain. *REC Interv Cardiol.* 2022
<https://doi.org/10.24875/RECICE.M22000340>

Disabling stroke	HR, 2.05	de Andrés-Nogales et al. 2017 ⁷
Aortic reintervention	HR, 2.21	PARTNER 3 trial ¹ Procedural deaths (0.4%) compared to monthly mortality Risk of overall mortality for 73 years old ^a (0.16%)

^a Average age of the PARTNER 3 cohort.

AF, atrial fibrillation; HR, hazard ratio; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation.

Table 3 of the supplementary data. Costs associated with TAVI and SAVR (procedure, complications, long-term)

Unit cost components	TAVI with SAPIEN 3	SAVR	Source
Procedure			
Intervention	€ 24 781	€ 13 779	Official unit costs data from the SERGAS ⁸ and resource use data informed by current clinical practice in low surgical risk patients in Galicia.
Rehabilitation	€ 114	€ 461	De Andrés-Nogales et al. 2015 ⁹
Acute postoperative complications			
Reintervention	€ 25 401	€ 32 117	Assumed equal to cost of initial procedure plus rehabilitation associated with the procedure
Associated to health states			
Treated AF – Month 1	€ 126	€ 126	Esquivias et al. 2015 ¹⁰ Rubio-Terrés et al. 2016 ¹¹
Treated AF ≥ Month 2	€ 89	€ 89	
Disabling stroke – Month 1	€ 6757	€ 6757	Oyagüez et al. 2020 ¹²
Disabling stroke ≥ Month 2	€ 2 08	€ 2308	
Caregiver for disabling stroke – Month 1	€ 1478	€ 1478	Alvarez-Sabín et al. 2017 ¹³
Caregiver for disabling stroke ≥ Month 2	€ 1478	€ 1478	
Alive and well – Year 1	€ 113	€ 113	Esquivias et al. 2015 ¹⁰
Alive and well – Year 2+	€ 38	€ 38	
Other costs considered			
Pacemaker implantation procedure	€ 7 841	€ 7 841	GRD APR, 2019 ¹⁴
Pacemaker implantation complications (monthly)	€ 56	€ 56	Crespo et al. 2020 ¹⁵
Rehospitalization	€ 3093	€ 3093	GRD APR, 2019 ¹⁴
Reintervention	€ 25 401	€ 32 117	Assumed equal to cost of initial procedure plus rehabilitation associated with the procedure

Table 4 of the supplementary data. Breakdown of TAVI and SAVR procedure costs

	TAVI	SAVR	
A. Previous diagnosis	Resource use		Cost in €
Structural intervention consultation	1	1	175
Transthoracic echocardiogram	1	1	321
Transesophageal echocardiogram	0	0	
CT- Angiography	0.7	0	377.36
Catheterization including radial approach	1	1	1055
Total A (resource use*cost)	1815.15	1551.00	

	TAVI	SAVR	
B. Intervention	Cost in €		
Personnel expenses	562	562	
Valve and material costs	19 000	6000	
Room costs	1030	1030	
Total B	20 592	7592	

	TAVI	SAVR	
C. Hospitalization	Resource use		Cost in €
ICU stay	1	2	1142.47
General ward stay	2	4	528.95
Total C (resource use*cost)	2200.37	4400.74	

	TAVI	SAVR
Total cost in € (Total A + Total B + Total C)	24 607.52	13 543.74
Total cost back in 2021 (in €)	24 781.30	13 778.52

Table 5 of the supplementary data. Deterministic sensitivity analysis input parameters

Parameter	Base case value	Lower value	Upper value	Lower (%)	Upper (%)
Age	73	64.97	84.97	11.0%	16.4%
Men	69%	64.79%	73.21%	6.1%	6.1%
Discount rate: costs (1–30 years)	3.0%	2.40%	3.60%	20.0%	20.0%
Discount rate: costs (> 30 years)	3.0%	2.40%	3.60%	20.0%	20.0%
Discount rate: benefits (1–30 years)	3.0%	2.40%	3.60%	20.0%	20.0%
Discount rate: benefits (> 30 years)	3.0%	2.40%	3.60%	20.0%	20.0%
TAVI with SAPIEN 3: 30-day mortality risk	0.4%	0.32%	0.48%	20.0%	20.0%
TAVI with SAPIEN 3: Risk of new onset of treated AF at 30 days	4.1%	3.26%	4.89%	20.0%	20.0%
TAVI with SAPIEN 3: Risk of new PP at 30 days	6.5%	5.16%	7.74%	20.0%	20.0%
TAVI with SAPIEN 3: Risk of DS at 30 days	0.0%	0.00%	0.4%	NA	NA
SAVR: 30-day mortality risk	1.1%	0.88%	1.32%	20.0%	20.0%
SAVR: Risk of new onset treated AF at 30 days	35.8%	28.62%	42.93%	20.0%	20.0%
SAVR: Risk of new PP at 30 days	4.0%	3.17%	4.76%	20.0%	20.0%
SAVR: Risk of DS at 30 days	0.4%	0.35%	0.53%	20.0%	20.0%
TAVI with SAPIEN 3: Alive and well to treated AF (monthly transition after 1 year)	0.1%	0.05%	0.08%	20.0%	20.0%

TAVI with SAPIEN 3: Alive and well to DS (monthly transition after 1 year)	0.004%	0.003%	0.005%	20.0%	20.0%
TAVI with SAPIEN 3: Treated AF to DS (monthly transition after 1 year)	0.009%	0.007%	0.011%	20.0%	20.0%
SAVR: Alive and well to treated AF (monthly transition after 1 year)	0.1%	0.09%	0.13%	20.0%	20.0%
SAVR: Alive and well to DS (monthly transition after 1 year)	0.004%	0.003%	0.005%	20.0%	20.0%
SAVR: Treated AF to DS (monthly transition after 1 year)	0.009%	0.007%	0.011%	20.0%	20.0%
TAVI with SAPIEN 3: Rehospitalization multiplier	1	0.8	1.2	20.0%	20.0%
SAVR: Rehospitalization multiplier	1	0.8	1.2	20.0%	20.0%
TAVI with SAPIEN 3: Reintervention multiplier	1	0.8	1.2	20.0%	20.0%
SAVR: Reintervention multiplier	1	0.8	1.2	20.0%	20.0%
RR of death for treated AF	1.5	1.39	1.54	4.8%	5.5%
RR of death with DS (month 1)	2.1	1.64	2.46	20.0%	20.0%
RR of death with DS (month 2+)	2.1	1.64	2.46	20.0%	20.0%
RR of death with TAVI reintervention with SAPIEN 3	2.2	1.77	2.66	20.0%	20.0%
RR of death with SAVR reintervention	2.2	1.77	2.65	20.0%	20.0%
HR mortality vs SAVR: TAVI with SAPIEN 3	0.8	0.35	1.63	53.3%	117.3%
Utility decrement: treated AF	0.17	0.14	0.21	20.0%	20.0%
Utility decrement: DS	0.42	0.34	0.50	20.0%	20.0%
Procedural cost: TAVI with SAPIEN 3	€ 25 401	€ 23 394	€ 35 091	7.9%	38.1%

Procedural cost: SAVR	€ 14 550	€ 11 640	€ 26 892	20.0%	84.8%
AE cost: TAVI with SAPIEN 3	€ 0	€ 0	€ 311	NA	NA
AE cost: SAVR	€ 0	€ 0	€ 1 281	NA	NA
AF cost: per month from month 2	€ 89	€ 71	€ 107	20.0%	20.0%
DS cost (month 1): per month	€ 8 235	€ 6 588	€ 9 882	20.0%	20.0%
DS cost (month 2+): per month	€ 3 786	€ 3 029	€ 4 543	20.0%	20.0%
Alive and well cost: per month (SAVR 2+)	€ 38	€ 30	€ 45	20.0%	20.0%
PP implantation cost	€ 7 841	€ 6 273	€ 9 409	20.0%	20.0%
PP complications (per month)	€ 56	€ 44	€ 67	20.0%	20.0%
Hospitalization cost for TAVI with SAPIEN 3	€ 3 093	€ 2 474	€ 3 711	20.0%	20.0%
Hospitalization costs for SAVR	€ 3 093	€ 2 474	€ 3 711	20.0%	20.0%
Reintervention cost for TAVI with SAPIEN 3	€ 25 401	€ 23 394	€ 35 091	7.9%	38.1%
Reintervention cost for SAVR	€ 32 117	€ 27 230	€ 40 845	15.2%	27.2%

AE, adverse events; AF, atrial fibrillation; DS, disabling stroke; HR, hazard ratio; PP, permanent pacemaker; RR, relative risk; SAVR, surgical aortic valve

replacement; TAVI, transcatheter aortic valve implantation.

Table 6 of the supplementary data. Probabilistic sensitivity analysis assumptions

Parameter	Base case value	Distribution	Parameters	Source
TAVI with SAPIEN 3 – clinical events at 30 days				
All-cause mortality	0.4%	Beta	Alpha = 2 / Beta = 494	PARTNER 3 trial ¹
New-onset treated AF	4.1%	Beta	Alpha = 17 / Beta = 400	
New permanent pacemaker implantation	6.5%	Beta	Alpha = 32 / Beta = 464	
Rehospitalization	3.4%	Beta	Alpha = 17 / Beta = 479	
Disabling stroke	0.0%	Beta	Alpha = 0 / Beta = 496	
Non-disabling stroke	0.6%	Beta	Alpha = 3 / Beta = 493	
TIA	0.0%	Beta	Alpha = 0 / Beta = 496	
MI	1.0%	Beta	Alpha = 5 / Beta = 491	
Bleeding	3.6%	Beta	Alpha = 18 / Beta = 478	
AKI with renal replacement therapy	0.2%	Beta	Alpha = 1 / Beta = 495	
Aortic reintervention	0.2%	Beta	Alpha = 1 / Beta = 495	
SAVR – clinical events at 30 days				
All-cause mortality	1.1%	Beta	Alpha = 5 / Beta = 449	PARTNER 3 trial ¹
New-onset treated AF	35.8%	Beta	Alpha = 132 / Beta = 237	

New permanent pacemaker implantation	4.0%	Beta	Alpha = 18 / Beta = 436	
Rehospitalization	6.4%	Beta	Alpha = 29 / Beta = 425	
Disabling stroke	0.4%	Beta	Alpha = 2 / Beta = 452	
Non-disabling stroke	2.0%	Beta	Alpha = 9 / Beta = 445	
TIA	0.7%	Beta	Alpha = 3 / Beta = 451	
MI	1.3%	Beta	Alpha = 6 / Beta = 448	
Bleeding	24.4%	Beta	Alpha = 111 / Beta = 343	
AKI with renal replacement therapy	0.7%	Beta	Alpha = 3 / Beta = 451	
Aortic reintervention	0.7%	Beta	Alpha = 3 / Beta = 451	
TAVI with SAPIEN 3 – Clinical events from 30 days to 1 year (monthly probability)				
TIA	0.09%	Beta	Alpha = 5 / Beta = 491	PARTNER 3 trial ¹
MI	0.02%	Beta	Alpha = 1 / Beta = 495	
Severe/life-threatening bleeding	0.4%	Beta	Alpha = 20 / Beta = 476	
Rehospitalization rate	0.35%	Gamma	SD = 0.01 (assumption)	
SAVR – Clinical events from 30 days to 1 year (monthly probability)				
TIA	0.04%	Beta	Alpha = 2 / Beta = 452	PARTNER 3 trial ¹
MI	0.08%	Beta	Alpha = 4 / Beta = 450	

Severe/life-threatening bleeding	0.1%	Beta	Alpha = 6 / Beta = 448	
Rehospitalization rate	0.4%	Gamma	SD = 0.01% (assumption)	
TAVI with SAPIEN 3 – Monthly transition probabilities (Month 1 to 12 and Month 13 onwards)				
Alive and well to Treated AF – Month 1 to Month 12	0.11%	Beta	Alpha = 5 / Beta = 395	PARTNER 3 trial ¹
Alive and well to Treated AF – Month 13 onwards	0.06%	Beta	Alpha = 3 / Beta = 392	
Alive and well to Disabling stroke	0.004%	Beta	Alpha = 46.2 / Beta = 99.954	SAFE ²
Treated AF to Disabling stroke	0.009%	Beta	Alpha = 55 / Beta = 587.812	Odutayo et al. 2016 ³
SAVR – Monthly transition probabilities (Month 1 to 12 and Month 13 onwards)				
Alive and well to Treated AF – Month 1 to Month 12	0.15%	Beta	Alpha = 4 / Beta = 233	PARTNER 3 trial ¹
Alive and well to Treated AF – Month 13 Onwards	0.11%	Beta	Alpha = 3 / Beta = 230	PARTNER 3 trial, 2-year outcomes ¹⁶
Alive and well to Disabling stroke	0.004%	Beta	Alpha = 46.2 / Beta = 99.954	SAFE ²
Treated AF to Disabling stroke	0.009%	Beta	Alpha = 55 / Beta = 587.812	Odutayo et al. 2016 ³
Other clinical event rates for both arms (TAVI and SAVR) – Annual risk				
Rehospitalization – Month 13 onwards	1.2%	Gamma	SD = 0.1% (assumption)	PARTNER 3 trial ¹
Reintervention rate – Year 1	0.5%	Gamma	SD = 0.05% (assumption)	PARTNER 3 trial up to 2 years ^{1,4} and thereafter ⁵
Reintervention rate – Year 2	0.4%	Gamma	SD = 0.04% (assumption)	

Reintervention rate – Year 3	0.2%	Gamma	SD = 0.02% (assumption)
Reintervention rate – Year 4	0.2%	Gamma	SD = 0.02% (assumption)
Reintervention rate – Year 5	0.1%	Gamma	SD = 0.01% (assumption)
Reintervention rate – Year 6	0.2%	Gamma	SD = 0.02% (assumption)
Reintervention rate – Year 7	0.3%	Gamma	SD = 0.03% (assumption)
Reintervention rate – Year 8	0.6%	Gamma	SD = 0.06% (assumption)
Reintervention rate – Year 9	0.8%	Gamma	SD = 0.08% (assumption)
Reintervention rate – Year 10	1.5%	Gamma	SD = 0.15% (assumption)
Reintervention rate – Year 11	1.8%	Gamma	SD = 0.18% (assumption)
Reintervention rate – Year 12	2.4%	Gamma	SD = 0.24% (assumption)
Reintervention rate – Year 13	2.7%	Gamma	SD = 0.27% (assumption)
Reintervention rate – Year 14	3.2%	Gamma	SD = 0.32% (assumption)
Reintervention rate – Year 15	3.9%	Gamma	SD = 0.39% (assumption)
Reintervention rate – Year 16	4.6%	Gamma	SD = 0.46% (assumption)
Reintervention rate – Year 17	5.5%	Gamma	SD = 0.55% (assumption)
Reintervention rate – Year 18	6.2%	Gamma	SD = 0.62% (assumption)
Reintervention rate – Year 19	7.2%	Gamma	SD = 0.72% (assumption)
Reintervention rate – Year 20	7.6%	Gamma	SD = 0.76% (assumption)

Reintervention rate – Year 21	7.9%	Gamma	SD = 0.79% (assumption)	
Reintervention rate – Year 22	8.6%	Gamma	SD = 0.86% (assumption)	
Reintervention rate – Year 23 onwards	8.9%	Gamma	SD = 0.89% (assumption)	
Relative risk of death (HR) associated with treated AF, disabling stroke, and reintervention – for both arms				
Treated AF	1.46	Lognormal	SD = 0.146 (assumption)	Odutayo et al. 2016 ³
Disabling stroke	2.05	Lognormal	SD = 0.205 (assumption)	De Andrés-Nogales et al. 2017 ⁷
Aortic reintervention	2.21	Lognormal	SD = 0.22 (assumption)	PARTNER 3 trial ¹ Procedural deaths (0.4%) compared to monthly mortality risk of general mortality for 73 years old (0.16%)
Disutilities associated to treated AF and disabling stroke – for both arms				
Utility decrement: Treated AF	0.17	Gamma	SD = 0.017 (assumption)	Oyagüez et al. 2020 ¹²
Utility decrement: Disabling stroke	0.42	Gamma	SD = 0.042 (assumption)	Lopez-Bastida et al. 2012 ¹⁷
Procedural cost (including rehabilitation)				
TAVI with SAPIEN 3	€ 25,401	Gamma	SD = 2,540 (assumption)	Official unit costs data from the SERGAS ⁸ and resource use data informed by current clinical practice in low surgical risk patients in Galicia.
SAVR	€ 14,550	Gamma	SD = 1,455 (assumption)	
Cost of postoperative complications				

TAVI reintervention with SAPIEN 3	€ 25 401	Gamma	SD = 2,540 (assumption)	Assumed equal to cost of initial procedure plus procedure related rehabilitation.
SAVR reintervention	€ 32 117	Gamma	SD = 3,211 (assumption)	
Monthly cost associated to health states (Alive & well, Treated AF, DS)				
Treated AF up to 30 days	€ 126	Gamma	SD = 12.6 (assumption)	Esquivias et al. 2015 ¹⁰ Rubio-Terrés et al. 2016 ¹¹
Treated AF – Month 2 onwards	€ 89	Gamma	SD = 8.9 (assumption)	GRD APR, 2019 ¹⁴
Disabling stroke (including caregiver) up to 30 days	€ 8235	Gamma	SD = 676 (assumption)	Oyagüez et al. 2020 ¹² Alvarez-Sabín et al. 2017 ¹³
Disabling stroke (including caregiver) – Month 2 onwards	€ 3786	Gamma	SD = 231 (assumption)	Pinar et al. 2021 ¹⁸
TAVI with SAPIEN 3: Alive and well up to 1 year	€ 113	Gamma	SD = 11.3 (assumption)	Esquivias et al. 2015 ¹⁰
SAVR: Alive and well up to 1 year	€ 113	Gamma	SD = 11.3 (assumption)	Esquivias et al. 2015 ¹⁰ Rubio-Terrés et al. 2016 ¹¹
Alive and well – Month 13 onwards (both arms)	€ 38	Gamma	SD = 3.8 (assumption)	
Other costs considered in the model – for both arms				
Monthly cost of pacemaker complications	€ 56	Gamma	SD = 5.6 (assumption)	Oyagüez et al. 2020 ¹² Alvarez-Sabín et al. 2017 ¹³ Crespo et al. 2020 ¹⁵
Rehospitalization	€ 3093	Gamma	SD = 309.3 (assumption)	GRD APR, 2019 ¹⁴

AF, atrial fibrillation; AKI, acute kidney injury; MI, myocardial Infarction; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation; TIA, transient ischemic attack.


Table 7 of the supplementary data. Scenario analyses results

		Incremental costs (TAVI vs SAVR)	Incremental QALYs (TAVI vs SAVR)	ICER
	Base case	€ 6971	1,00	€ 6952/ QALY
Scenario #1	Increased risk of TAVI reintervention (RR from PARTNER 2A)	€ 16 804	0.99	€ 17 041/ QALY
Scenario #2	Increased risk of stroke to align with PARTNER 3 outcomes	€ 19 707	0.81	€ 24 424/ QALY
Scenario #3	Survival data from PARTNER 3	€ 7630	1.60	€ 4763/ QALY
Scenario #4	No survival benefit with TAVI	€ 4866	0.70	€6903/ QALY
Scenario #5	Use of health-related quality of life data based on treatment from PARTNER 3	€ 6971	0.46	€ 15 157/ QALY
Scenario #6a	Official unit costs and resource use data from Murcia (2015)	-€ 1234	1.00	Dominant
Scenario #6b	Base case procedure cost input updated (values for hospital LoS and SAVR valve costs) based on KOL hospital/clinical experience in Huelva region	€ 3999	1.00	€ 3988/ QALY
Scenario #6c	Unit costs and resource use data from OSTEBA 2014 HTA with hospital LoS updated to show the current clinical practice.	€ 3340	1.00	€ 3331/ QALY
Scenario #7	Adverse event costs included within 30 days	€ 5879	1.00	€ 5863/ QALY
Scenario #8	Timespan = 5 years	€ 9360	0.30	€ 31 668/ QALY
Scenario #9	Timespan = 10 years	€ 8077	0.56	€ 14 451/ QALY

Scenario #10	Timespan = 15 years	€ 7231	0.78	€ 9318/ QALY
Scenario #11	Timespan = 20 years	€ 6928	0.92	€ 7529/ QALY
Scenario #12	Timespan = 30 years	€ 6962	1.11	€ 6970/ QALY

AE, adverse event; ICER, incremental cost-effectiveness ratio; LoS, length of stay; QALY, quality adjusted life years; RR, relative risk; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation.

Figure 1 of the supplementary data. Cost breakdown for TAVI with SAPIEN 3 and SAV.



AE, adverse event; AF, atrial fibrillation; MI, myocardial infarction; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation; TIA, transient ischemic attack.

Vázquez Rodríguez JM, et al. Cost-effectiveness of SAPIEN 3 transcatheter aortic valve implantation in low surgical mortality risk patients in Spain. *REC Interv Cardiol.* 2022
<https://doi.org/10.24875/RECICE.M22000340>

REFERENCES

1. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Replacement With a Balloon-Expandable Valve in Low-Risk Patients. *N Engl J Med.* 2019;380:1695-1705.
2. SAFE 2017. The Burden of Stroke in Spain. Available online: https://www.safestroke.eu/wp-content/uploads/2017/12/SAFE_STROKE_SPAIN.pdf Accessed 22 May 2022.
3. Odutayo A, Wong CX, Hsiao AJ, et al. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. *BMJ.* 2016;354:i4482.
4. Leon MB, Mack MJ, Hahn RT, et al. Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk. *J Am Coll Cardiol.* 2021;77:1149-1161.
5. Bourguignon T, Bouquiaux-Stablo A-L, Candolfi P, et al. Very long-term outcomes of the Carpentier-Edwards Perimount valve in aortic position. *Ann Thorac Surg.* 2015;99:831-837.
6. Instituto Nacional de Estadística. National Life Tables Spain (2019) Available online: https://www.ine.es/dyngs/INEbase/en/operacion.htm?c=Estadistica_C&cid=1254736177004&menu=ultiDatos&idp=1254735573002 Accessed 22 May 2022.
7. de Andrés-Nogales F, Álvarez M, de Miquel MÁ, et al. Cost-effectiveness of mechanical thrombectomy using stent retriever after intravenous tissue plasminogen activator compared with intravenous tissue plasminogen activator alone in the treatment of acute ischaemic stroke due to large vessel occlusion in Spain. *Eur Stroke J.* 2017;2:272-284.
8. SERGAS 2014. DECRETO 56/2014, de 30 de abril, por el que se establecen las tarifas de los servicios sanitarios prestados en los centros dependientes del Servicio Gallego de Salud y en las fundaciones públicas sanitarias. DOG 96. 2014. Available online: https://www.xunta.gal/dog/Publicados/2014/20140521/AnuncioC3K1-140514-0001_es.html Accessed 22 May 2022.

Vázquez Rodríguez JM, et al. Cost-effectiveness of SAPIEN 3 transcatheter aortic valve implantation in low surgical mortality risk patients in Spain. *REC Interv Cardiol.* 2022
<https://doi.org/10.24875/RECICE.M22000340>

9. de Andrés-Nogales F, Vivancos Mora J, Barriga Hernández FJ, et al. Use of healthcare resources and costs of acute cardioembolic stroke management in the Region of Madrid: The CODICE Study. *Neurología.* 2015;30:536-544.

10. Esquivias, GB, Albaladejo GE, Zamorano JL, et al. Cost-effectiveness analysis comparing apixaban and acenocoumarol in the prevention of stroke in patients with nonvalvular atrial fibrillation in Spain. *Rev Esp Cardiol.* 2015;68:680-690.

11. Rubio-Terrés, C, Graefenhain de Codeset R, Rubio-Rodríguez D, Evers T, Grau Cerrato SG. Cost-effectiveness analysis of rivaroxaban vs acenocoumarol in the prevention of stroke in patients with non-valvular atrial fibrillation in Spain. *JHEOR.* 2016;4:19-34.

12. Oyagüez I, Suárez C, López-Sendón JL, et al. Cost-Effectiveness Analysis of Apixaban Vs Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention. *Pharmacoecon Open.* 2020;4:485-497.

13. Alvarez-Sabín J, Quintana M, Masiuan J, et al. Economic impact of patients admitted to stroke units in Spain. *Eur J Health Econ.* 2017;18:449-458.

14. Ministerio de Sanidad de España. GRD APR 190/191 (2019). Registro de Altas de los Hospitales Generales del Sistema Nacional de Salud. CMBD. Norma Estatal de Años Anteriores Available online: <https://www.sanidad.gob.es/estadEstudios/estadisticas/cmbdAnteriores.htm> Accessed 22 May 2022.

15. Crespo C, Linhart M, Acosta J, et al. Optimisation of cardiac resynchronisation therapy device selection guided by cardiac magnetic resonance imaging: cost-effectiveness analysis. *Eur J Prev Cardiol.* 2020;27:622-632.

16. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. *N Engl J Med.* 2016; 374: 1609-1620.

17. Lopez-Bastida J, Oliva Moreno J, Worbes Cerezo M, et al. Social and economic costs and health-related quality of life in stroke survivors in the Canary Islands, Spain. *BMC Health Serv Res.* 2012;12:315.

Vázquez Rodríguez JM, et al. *Cost-effectiveness of SAPIEN 3 transcatheter aortic valve implantation in low surgical mortality risk patients in Spain. REC Interv Cardiol. 2022*
<https://doi.org/10.24875/RECICE.M22000340>

18. Pinar E, García de Lara J, Hurtado J, et al. Análisis coste-efectividad del implante percutáneo de válvula aórtica SAPIEN 3 en pacientes con estenosis aórtica grave sintomática. *Rev Esp Cardiol.* 2021;75:325-333.